These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35982307)

  • 1. Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.
    Hagey RJ; Elazar M; Pham EA; Tian S; Ben-Avi L; Bernardin-Souibgui C; Yee MF; Moreira FR; Rabinovitch MV; Meganck RM; Fram B; Beck A; Gibson SA; Lam G; Devera J; Kladwang W; Nguyen K; Xiong A; Schaffert S; Avisar T; Liu P; Rustagi A; Fichtenbaum CJ; Pang PS; Khatri P; Tseng CT; Taubenberger JK; Blish CA; Hurst BL; Sheahan TP; Das R; Glenn JS
    Nat Med; 2022 Sep; 28(9):1944-1955. PubMed ID: 35982307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
    Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy.
    Pelz L; Rüdiger D; Dogra T; Alnaji FG; Genzel Y; Brooke CB; Kupke SY; Reichl U
    J Virol; 2021 Nov; 95(24):e0117421. PubMed ID: 34550771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus.
    Baek YB; Kwon HJ; Sharif M; Lim J; Lee IC; Ryu YB; Lee JI; Kim JS; Lee YS; Kim DH; Park SI; Kim DK; Kim JS; Choy HE; Lee S; Choi HS; Osborne TF; Jeon TI; Cho KO
    Signal Transduct Target Ther; 2022 Oct; 7(1):367. PubMed ID: 36253361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and Functional RNA Motifs of SARS-CoV-2 and Influenza A Virus as a Target of Viral Inhibitors.
    Szczesniak I; Baliga-Gil A; Jarmolowicz A; Soszynska-Jozwiak M; Kierzek E
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.
    Du X; Zuo X; Meng F; Han C; Ouyang W; Han Y; Gu Y; Zhao X; Xu F; Qin FX
    Cell Prolif; 2021 Jan; 54(1):e12953. PubMed ID: 33211371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo secondary structural analysis of Influenza A virus genomic RNA.
    Mirska B; Woźniak T; Lorent D; Ruszkowska A; Peterson JM; Moss WN; Mathews DH; Kierzek R; Kierzek E
    Cell Mol Life Sci; 2023 May; 80(5):136. PubMed ID: 37131079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
    Abbott TR; Dhamdhere G; Liu Y; Lin X; Goudy L; Zeng L; Chemparathy A; Chmura S; Heaton NS; Debs R; Pande T; Endy D; La Russa MF; Lewis DB; Qi LS
    Cell; 2020 May; 181(4):865-876.e12. PubMed ID: 32353252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intranasal ASO therapeutic targeting SARS-CoV-2.
    Zhu C; Lee JY; Woo JZ; Xu L; Nguyenla X; Yamashiro LH; Ji F; Biering SB; Van Dis E; Gonzalez F; Fox D; Wehri E; Rustagi A; Pinsky BA; Schaletzky J; Blish CA; Chiu C; Harris E; Sadreyev RI; Stanley S; Kauppinen S; Rouskin S; Näär AM
    Nat Commun; 2022 Aug; 13(1):4503. PubMed ID: 35922434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 and influenza: a comparative overview and treatment implications.
    Manzanares-Meza LD; Medina-Contreras O
    Bol Med Hosp Infant Mex; 2020; 77(5):262-273. PubMed ID: 33064680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient Inhibition of Avian and Seasonal Influenza A Viruses by a Virus-Specific Dicer-Substrate Small Interfering RNA Swarm in Human Monocyte-Derived Macrophages and Dendritic Cells.
    Jiang M; Österlund P; Westenius V; Guo D; Poranen MM; Bamford DH; Julkunen I
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30463970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative antiviral approaches to combat influenza A virus.
    Wong KH; Lal SK
    Virus Genes; 2023 Feb; 59(1):25-35. PubMed ID: 36260242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
    Schäfer A; Martinez DR; Won JJ; Meganck RM; Moreira FR; Brown AJ; Gully KL; Zweigart MR; Conrad WS; May SR; Dong S; Kalla R; Chun K; Du Pont V; Babusis D; Tang J; Murakami E; Subramanian R; Barrett KT; Bleier BJ; Bannister R; Feng JY; Bilello JP; Cihlar T; Mackman RL; Montgomery SA; Baric RS; Sheahan TP
    Sci Transl Med; 2022 May; 14(643):eabm3410. PubMed ID: 35315683
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.